A potential coronavirus vaccine developed by Oxford University with pharmaceutical giant AstraZeneca has produced a promising immune response in a large, early-stage human trial, according to newly released data published Monday in the medical journal The Lancet.

The researchers are calling their experimental vaccine ChAdOx1 nCoV-19 (AZD1222). It combines genetic material from the coronavirus with a modified adenovirus that is known to cause infections in chimpanzees. The phase one trial had more than 1,000 participants in people ages 18 to 55.

For reading full text click the link.